In this episode, David interviews Joost Breeksema: philosopher, researcher, and Executive Director of the OPEN Foundation, which manages the Interdisciplinary Conference on Psychedelic Research (ICPR) – Europe’s longest-running conference on psychedelics.
He discusses the use of psychedelics in consciousness research; his concerns over psychedelic infrastructure scaling too quickly and people not being adequately trained; drug policy in the Netherlands, coffee shops, and the interesting loophole with psychedelic truffles; how harm reduction approaches actually work; and finding the proper balance between hype and hope. And he asks some interesting questions: How is research influenced by researchers consulting for psychedelic companies? Are there potential business models outside shareholder-profit models? Are there better ways to design psychedelic studies?
And of course, he talks a lot about this year’s ICPR conference, which is taking place at the Philharmonie Haarlem (just outside Amsterdam) from September 22nd to the 24th. Two big parts of this year’s conference are discussing how science, ethics, and business interact with highly scientific academic research, and looking at clinical perspectives in comparison to patient perspectives (as patients are not represented anywhere near enough). This year, they added an extra day before the conference (the 21st) dedicated more to business-oriented matters, as well as having workshops on music, breathwork, and psychotherapy and psychedelics. Joe, Kyle, and Johanna will be there, and after recording this podcast, it sure sounds like David will be too.
When signing up, use code TODAY150 at checkout for 150€ off!
“One of the areas that [is] most intriguing about psychedelic treatments is that they confront people with their own existence, with their place in the universe, with how they relate to themselves and to others; and that’s something, I think, as you said beautifully; it’s something that distinguishes psychedelic treatments from basically all conventional treatments.”
“Since the 70s in the Netherlands, we’ve pioneered harm reduction approaches. This has worked really well for people consuming more addictive substances [like] heroin, cocaine, [and] crack cocaine. We’ve always had a very pragmatic, public health-oriented view. We’ve never criminalized drug use or drug users, and as a result, we have, I think, probably the lowest prevalence of heroin users in all of Europe.”
“I think one of the key reasons for decriminalizing drug use is that it would de-marginalize people. This is the foundation of our drug policy for over 40 years. This was one of the key insights that they had when they formulated our drug policy, is that it’s not drug use per se that leads to more harmful drug use; it’s being marginalized and being criminalized that puts people quite literally to the margins.”
“I am personally convinced that in order to be an effective therapist, you need to have experience with the substance that you’re prescribing. You need to understand the terrain that patients are navigating through. …[But] if you’re a novice in psychedelic therapy, is having one experience enough? And if not, how many is enough? And do you need to have a difficult experience as well? If you have three positive experiences that go in a specific direction, do you run the risk of imposing your own experience on how you interpret patient experiences? And if that’s not the case, then how do you make sure that you stay open-minded and you don’t impose your own value system or your own way of understanding the world on patients?”
About Joost Breeksema
Joost Breeksema is the executive director of the OPEN Foundation. Founded in 2007, the Amsterdam-based non-profit organization has been on the forefront, advocating for psychedelic research and therapies. He also directs the organization of the Interdisciplinary Conference on Psychedelic Research (ICPR); Europe’s longest-running conference on psychedelics, which will return to Amsterdam from 21 to 24, September 2022. ICPR focuses on high-quality scientific psychedelic research, therapeutic innovations, and critical engagement around ethics, policy, the psychedelic industry boom, and more. Joost is a philosopher and qualitative researcher. For his Ph.D. at the Department of Psychiatry (UMCG), he interviews patients about their treatment experiences with ketamine, psilocybin, and MDMA, aiming to deepen our understanding of the therapeutic mechanisms and the role of setting and support. Underlying all his work is a deep-seated belief in the scientifically-grounded, responsible, and ethical integration of psychedelics that respects the multiplicity of other, non-medical approaches. He advocates for critical, collaborative, open, and transparent approaches in science and beyond.
Support the show!
- Leave us a review on Facebook or iTunes
- Share us with your friends
- Join our Facebook group – Psychedelics Today group – Find the others and create community.